Elicio Therapeutics (NASDAQ:ELTX – Free Report) had its price target decreased by B. Riley Financial to $8.00 in a research report report published on Thursday,Benzinga reports. B. Riley Financial currently has a buy rating on the stock.
Other research analysts have also recently issued reports about the stock. Rodman & Renshaw reaffirmed a “buy” rating on shares of Elicio Therapeutics in a report on Monday, June 15th. LADENBURG THALM/SH SH started coverage on Elicio Therapeutics in a research note on Thursday, June 18th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings cut Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. JonesTrading downgraded Elicio Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Elicio Therapeutics in a research report on Tuesday, August 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.00.
Check Out Our Latest Research Report on Elicio Therapeutics
Elicio Therapeutics Price Performance
Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.11. Analysts forecast that Elicio Therapeutics will post -2.1 EPS for the current fiscal year.
Institutional Trading of Elicio Therapeutics
Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Elicio Therapeutics during the 2nd quarter worth approximately $2,995,000. Deutsche Bank AG acquired a new stake in Elicio Therapeutics during the 2nd quarter valued at $49,000. Bank of New York Mellon Corp acquired a new stake in Elicio Therapeutics during the 2nd quarter valued at $62,000. Bank of America Corp DE increased its position in Elicio Therapeutics by 1,225.2% during the first quarter. Bank of America Corp DE now owns 15,333 shares of the company’s stock worth $164,000 after buying an additional 14,176 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Elicio Therapeutics by 332.7% during the first quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after buying an additional 93,520 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing cancer immunotherapies designed to activate and strengthen the immune system’s response to tumors. The company’s approach is based on its Amphiphile technology, which is intended to direct therapeutic agents to lymph nodes, where immune responses are initiated and expanded.
Elicio’s leading program, ELI-002, is an investigational therapeutic cancer vaccine targeting common KRAS mutations. The program is being studied in patients with certain solid tumors, including pancreatic and colorectal cancers, with the goal of treating minimal residual disease and reducing the risk of recurrence.
Read More
- Five stocks we like better than Elicio Therapeutics
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for Elicio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elicio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
